BIBLIOGRAFÍA 1) Abbas AK, Lichtman AH, Pober JS. Antibodies and antigens. En: Cellular and Molecular Immunology, 2nd ed. Philadelphia:W.B. Saunders Company. 1994:33-64. 2) Rojas W. Inmunidad humoral - Linfocito B. En: Inmunología, 10ma ed. Colombia:Corporación para la Investigación Biológica. 1995:92-110 3) Carayannopoulos L, Capra D. Inmunoglobulins: Structure and function. En: Paul WE. Fundamental Inmunology, 3rd ed. New York:Raven Press. 1993:283-314. 4) Alzari PM, Lascombe M, Poljak RJ. Three-dimensional structure of antibodies. Ann Rev Immunol1988;6:555-80.
5) Tonegawa S. Somatic generation of antibody diversity. Nature1983;302:575-81. 7) Maloney DG, Levy R, Campbell MJ. Monoclonal antibody therapy. En: Mendelsohn J, Howley PM, Israel MA, Liotta LA. The Molecular Basis of Cancer, Philadelphia:W.B. Saunders Company,1995:460-510. 8) Hosono M, Endo K, Sakahara H, et al. Human/mouse chimeric antibodies show low reactivity with human anti-murine antibodies (HAMA). Br J Cancer 1992;65:197-203. 9) Shaw DR, Khazaeli MB, LoBuglio AF. Mouse/human chimeric antibodies to a tumour-associated antigen: Biologic activity of the four human IgG subclasses. J Natl Cancer Inst 1988;80:1553-58. 10) Co MS, Queen C: Humanised antibodies for therapy. Nature 1991;351:501-13. 11) Chaudhary VK, Queen C Junghans RP, et al. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 1989;339:394-99. 12) Huse WD, Sastry L, Iverson SA, et al. Generation of a large combinatorial library of the inmunoglobulin repertoire en phage lambda. Science 1989;246:1275-82. 13) Anderson KC, Bates MP, Slaughenhoupt BL, et al. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984;63:1424-33. 14) Reff ME, Camer K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45. 15) Mathas S, Kommert K, Dörken B, et al. Anti-CD20 antibody mediated apoptosis is dependent on caspase 3 activation [Abstract 1671]. Blood 1998;92:405a. 16) Nadler LM, Ritz J, Hardy R, et al. A unique cell surface antigen identifying lymphoid malignancies of B cells origin. J Clin Invest 1981;67:134-40. 17) Maloney DG, Smith B, Appelbaum FR. The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin’s lymphoma (NHL) cell lines [Abstract 2537]. Blood 1996;88-637a. 18) Maloney DG, Liles TM, Czerwinsky DK, et al. Phase I Clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84:2457-66. 19) Maloney DG, Grillo-López AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma. J Clin Oncol 1997;15:3266-74. 20) Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low grade non-Hodgkin’s lymphoma. Blood 1997;90:2188-95. 21) McLaughin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four dose treatment program. J Clin Oncol 1998;16:2825-33. 22) Solal-Celigny et al. Rituximab as firtst line treatment of patient with follicular lymphoma (FL) and low burden tumor: Clinical and molecular evaluation. [Abstract 2802]. 41st annual meeting of the American Society of Hematology 1999. 23) Grillo-López et al. Responders to Rituximab show continued tumor regression over time and a progression free survival that correlates with response classification. [Abstract 390]. 41st annual meeting of the American Society of Hematology 1999. 24) Davis T, Levy R, White CA, et al. Rituximab: Phase II (PII) retreatment (RrRx) study in patients (pts) with low-grade or follicular (LG/F) NHL [Abstract 1710]. Blood 1998;92:(10 Suppl 1):414a. 25) Czuczman MS, Grillo-López AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268-76. 26) Czuczman et al. Rituximab/CHOP chemoimmunotherapy in patients with low grade lymphoma (LG/F NHL): Free survival after three years (median) follow-up. [Abstract 432]. 41st annual meeting of the American Society of Hematology 1999. 27) Foram JM, Cunningham D, Coiffier B, et al. Immunotherapy of mantle cell lymphoma/ MCL with Rituximab (Rmab): duration of response & analysis of factors associated with response [Abstract 101]. Ann Oncol 1999;10 (Suppl 3):33. 28) Ghielmini M, Hsu-Schmitz SF, Burky K, et al.The effect of Rituximab on patients with follicular and mantle cell lymphoma [Abstract 102]. Ann Oncol 1999;10 (Suppl 3):33. 29) Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927-32. 30) Vose JM, Link BK, Grossbard MI, et al. Phase II study of Rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate or high-grade non-Hodgkin’s lymphoma (NHL) [Abstract 195]. Ann Oncol 1999;10(Suppl 3):58. 31) Brugger W. Manz M, Grunebach F, et al. Anti-CD20 Rituximab treatment after high-dose therapy and CD34+ blood stem cell transplant for newly diagnosed follicular and mantle cell non-Hodgkin’s lymphoma [Abstract 622]. Ann Oncol 1999;10(Suppl 3):169. 32) Flinn IW, O’Donnell P, Noga SJ, et al. In vivo purging and adjuvant immunotherapy with Rituximab during PBSC transplant for NHL [Abstract 259]. Ann Oncol 1999;10(Suppl 3):75. 33) Buckstein R, Imrie K, Spaner D, et al. In vivo purging with Rituxan: effects in stem cell mobilization efficacy, harvest purity, cytokine profile and engraftment in patients with relapsed follicular lymphoma undergoing autologous [Abstract 613]. Ann Oncol 1999;10(Suppl 3):167. 34) Data on file. Laboratorios Roche. 35) Perry CM, Wiseman LR.Trastuzumab. Biodrugs 1999;12:129-35. 36) Venter DJ, Tuzi NL, Kumar S, et al. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: Immuno-histological assessment correlates with gene amplification. Lancet 1987;2:69-72. 37) Lonardo F, Di Marco E, King CR, et al. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in thje absence of ligand. New Biol 1990;2:992-1003. 38) Bishop JM. Molecular themes on oncogenesis. Cell 1991;64:235-48. 39) Bishop JM. Viral oncogenes. Cell 1985;42:23-38. 40) Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82. 41) Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989;244:707-12. 42) Charpin C, Bonnier P, Khouzami A, et al. Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-HER-2/neu, pS2, cathepsinj, ER and PR. Anticancer Res 1992;12:591-8. 43) Seshadri R, Firgaira FA, Horsfall DJ, et al. Clinical significance of HE-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 1993;11:1936-42. 44) Allred DC, Clark GM, Tandon AK, et al. HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcionoma. J Clin Oncol 1992;10:599-605. 45) Yuan J, Hennessy C, Givan AL, et al. Predicting outcome for patients with node negative breast cancer: A comparative study of the value of flow citometry and cell image analysis for determination of DNA ploidy. Br J Cancer 1992;65:461-5. 46) Gusterson BA, Gelber RD, Goldhirsch S, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992;10:1049-56. 47) Bianchi S, Paglierani M, Zampi G, et al. Prognostic significance of c-erbB-2 expression in node negative breast cancer. Br J Cancer 1993;67:625-9. 48) Noguchi M, Koyasaki N, Ohta N, et al. C-erbB-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patiens with axillary lymph node-positive breast cancer. Cancer 1992;69:2953-60. 49) Clahsen PC, van de Velde CJH, Duval C, et al. P53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node negative breast cancer. J Clin Oncol 1998;16:470-9. 50) Elledge RM, Green S, Ciocca D, et al. HER-2 expression and response to tamoxifen in estrogen receptor-breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 1998;4:7-12. 51) Carlomagno C, Perrone F, Gallo C, et al. C-erbB-2 over-expression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastasis. J Clin Oncol 1996;14:2702-8. 52) Paik S, Bryant J, Park C, et al. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90:1361-70. 53) Pupa SM, Ménard S, Morelli D, Pozzi B, De Palo G, Colnaghi MI. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 1993;8:2917-23. 54) Scott GK, Robles R, Park JW, et al. A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol Cell Biol 1993;13:2247-57. 55) Gebhardt F, Zänker KS, Brandt B. Differential expression of alternatively spliced c-erbB-2 mRNA in primary tumors, lymph node metastases, and bone marrow micrometastases from breast cancer patients. Biochem Biophys Res Commun 1998;247:319-23. 56) Leitzel K, Teramoto Y, Konrad K, et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995;13:1129-35. 57) Yamauchi H, O’Neill A, Gelman R, et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1997;15:2518-25. 58) Yang L, Liocheva V, Colvin OM, Harris LN. Different response to adriamycin vs Cytoxan-based chemotherapy in ErbB2 positive breast cancer is associated with alteration in topoisomerasa IIa (topo IIa) expression [Abstract]. Breast Cancer Res Treat 1998;50:231. 59) Molina R, Jo J, Filella X, et al. C-erbB-2 oncoprotein, CEA and CA 15.3 in patiens with breast cancer: prognostic value. Breast Cancer Res Treat 1998;51:109-19. 60) Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpression human breast cancer xenografts. Cancer Res 1998; 582825-31. 61) Pietras RJ, Pegram MD, Finn RS, et al. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998;17:2235-49. 62) Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Semin Oncol 1999;26(Suppl 12):71-7. 63) Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185 HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-44. 64) Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185 HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpression metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;8:2659-71. 65) Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized, multinational controlled phase III trial [Abstract]. Proc Am Soc Clin Oncol 1998;17:98a. 66) Norton et al. Overall survival advantage to simultaneous chemotherapy plus the humanizes anti-HER2 monoclonal antibody herceptin in HER2 overexpressing (HER2+) metastatic breast cancer.[Abstract 483]. 35th annual meeting of the American Society of Clinical Oncology 1999. 67) Cobleigh MA, Vogel CL, Tripathy D, et al. Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer [Abstract]. Proc Am Coc Clin Oncol 1998;17:97a. 68) Fornier M, et al. Weekly herceptin + 1 hour taxol: Phase II study in HER2 overexpressing (HER2+) and non-overexpressing (HER2-) metastatic breast cancer. [Abstract 482]. 35th annual meeting of the American Society of Clinical Oncology 1999. 69) Burris HA, Hainesworth JD, Albain K, Huntington M, et al. Phase II trial of docetaxel and Herceptin® as first-or second- line chemotherapy for women with metastatic breast cancer whose tumours overexpress HER2. ECCO 99. 70) Pegram M, Slamon D. Herceptin® plus cisplatin is active in patients with metastatic breast cancer. ECCO 99. 71) Osoba D, Burchmore M. Health-related quality of life in women with metastatic breast cancer treated with trastuzumab (Herceptin). Semin Oncol 1999;26(Suppl 12):84-88. 72) Lieberman [Abstract 16613]. Health-related quality of life in metastatic breast cancer patients who responded to anti-HER2 therapy over 48 weeks. ECCO 99 73) Baselga J, Kerrigan M, Burchmore M. Ash M. Health-related quality of life (HRQL) in women with HER2-overexpressing metastatic breast cancer (MBC) in a phase III study of Herceptin® plus chemotherapy versus chemotherapy alone. ECCO 99 74) Aaronson NK, Ahmedzai S, Bergman B, et al. The european organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76. 75) Ewer MS, Gibbs HR, Swafford J, Benjamin RS. Cardiotoxicity in patients receiving trastuzumab (Herceptin): primary toxicity, sinergistic or sequential stress, or surveillance artifact?. Semin Oncol 1999;26(Suppl 12):96-101. 76) Gottlinger HG, Funke I, Hohnson JP, et al. The epithelial cell surface antigen PANOREX, a target for antibody-mediated tumor therapy: Its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer 1986;38:47-53. 77) Sears HF, Mattis J, Herlyn D, et al. Phase-1 clinical trials of monoclonal antibody in treatment of gastrointestinal tumors. Lancet 1982;1:762-65. 78) Blottière HM, Steplewski Z, Herlyn D, et al. Human antimurine immunoglobulin responses and immune functions in cancer patients receiving murine monoclonal antibody therapy. Hum Antibodies Hybridomas 1991;2:16-25. 79) Herlyn D, Harris D, Azloudik J, et al. Immunomodulatory activity of monoclonal anti-idiotypic antibody to anticolorectal carcinoma antibody CO17-1A in animals and patients. J Immunother 1994;15:303-11. 80) Fagerbert J, Ragnhammar P, Liljefors M, et al. Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A. Cancer Immunol Immunother 1996;42:81-7. 81) Frödin JE, Faxas ME, Hagström B, et al. Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (ab1). Relation to the clinical outcome -an important antitumoral effector function? Hybridoma 1991;10:421-31. 82) Holz E, Gruber R, Riethmüller G, et al. Monoclonal antibodies in cancer therapy: new perspectives after the colorectal carcinoma trial. Clin Immunother 1996;5:214-22. 83) Shen JW, Atkinson B, Koprowski H, et al. Binding of murine immunoglobulin to human tissues after immunotherapy with anticolorectal carcinoma monoclonal antibody. Int J Cancer 1984;33:465-68. 84) Sears HF, Herlyn D, Steplewski Z, et al. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J Biol Response Modif 1984; :138-50. 85) Sears HF, Herlyn D, Steplewski Z, et al. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res 1985;45:5910-13. 86) LoBuglio AF, Saleh MN, Lee J, et al. Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. J Natl Cancer Inst 1988;17:932-36. 87) Riethmuller G, Holz E, Schlimok G, et al. Monoclonal antibody therapy for resected Dukes C colorectal cancer: Seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998;1788-94. 88) Ragnhammar P, Fagerber J, Frödin JE, et al. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma: long lasting, complete remissions can be induced. Int J Cancer 1993;53:751-58. 89) Schöber C, Schulze M, Schlimok G, et al. Open label pilot study of monoclonal antibody 17-1A in combination with 5-fluorouracil/levamisole or 5-FU/folinic acid in patients with advanced colorectal cancer [abstract]. Proc Am Soc Clin Oncol 1996;15:229. 90) Saleh MN, LoBuglio AF, Wheeler RH, et al. A phase II trial of murine monoclonal antibody 17-1A and interferon-g: clinical and immunological data. Cancer Immunol Immunother 1990;32:185-90. 91) Weiner LM, Moldofsky PJ, Gatenby RA, et al. Antibody delivery and effector cell activation in a phase II trial of recombinant g-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma. Cancer Res 1988;48:2568-73. 92) Weiner LM, Harvey E, Padavic-Shaller K, et al. Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1A therapy in pancreatic carcinoma. J Immunother 1993;13:110-16. 93) Tempero MA, Sivinski C, Steplewski Z, et al. Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: biologic and clinical effects. J Clin Oncol 1990;8:2019-26. 94) Hempel D, Orucio D, Müller P, et al. Transplantation of ex vivo tumor cell purged PBSCT in breast cancer patients treated with high dose chemotherapy followed by supplementary immunotherapy with MOAB 17-1A phase I study [abstract]. Proc Am Soc Clin Oncol 1998;17:145a. 95) Schmoll HJ, Quietzsch D, Börner P, et al. Safety of adjuvant mAb 17-1A in colorectal cancer (CRC) [Abstract]. Eur J Cancer 1997;33 Suppl.8: S168. |
